DU Sheng-Li, Yang Xin-Chun, Zhong Jiu-Chang, Wang Le-Feng, Fan Yi-Fan
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
J Geriatr Cardiol. 2020 Nov 28;17(11):674-679. doi: 10.11909/j.issn.1671-5411.2020.11.004.
Elabela (ELA) was newly discovered as a novel endogenous ligand of the apelin receptor (APJ) which has demonstrated to be crucial for cardiovascular disease such as myocardial infarction, hypertension and heart failure. Previous experiments have revealed that ELA reduced arterial pressure and exerted positive inotropic effects on the heart. However, the role of plasma ELA levels in patients with acute coronary syndrome (ACS) and its relationship with severity of coronary arteries have not been investigated.
Two hundred and one subjects who were hospitalized for chest pain and underwent coronary angiography were recruited in this study. One hundred and seventy five patients were diagnosed with ACS and twenty-six subjects with negative coronary angiography were included in the control group. Plasma ELA levels, routine blood test, blood lipid, liver and kidney functions were measured. The number of coronary arteries and SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score of coronary lesions were used to evaluate the extent of coronary artery stenosis.
ELA in patients with ACS was significantly higher than that in the control group ( < 0.01). There was no significant difference in plasma ELA levels among patients with single-, double- and triple-vessel diseases. However, in the generalized additive model (GAM), there was a threshold nonlinear correlation between the ELA levels and Syntax I score ( < 0.001). Plasma ELA levels were positively correlated with the Syntax I score when the ELA levels ranged from 63.47 to 85.49 ng/mL. There was no significant association between the plasma ELA levels and the extent of coronary artery stenosis when the ELA levels were less than 63.47 ng/mL or higher than 85.49 ng/mL.
The present study demonstrates for the first time that plasma ELA levels are increased in patients with ACS. The rise in endogenous ELA levels was associated with severity of coronary stenosis and may be involved in the pathogenesis of ACS.
艾拉贝拉(ELA)是新发现的一种新型内源性血管生成素受体(APJ)配体,已证明其对心血管疾病如心肌梗死、高血压和心力衰竭至关重要。先前的实验表明,ELA可降低动脉血压并对心脏产生正性肌力作用。然而,血浆ELA水平在急性冠状动脉综合征(ACS)患者中的作用及其与冠状动脉严重程度的关系尚未得到研究。
本研究招募了201名因胸痛住院并接受冠状动脉造影的受试者。175例患者被诊断为ACS,26例冠状动脉造影阴性的受试者被纳入对照组。检测血浆ELA水平、血常规、血脂、肝肾功能。冠状动脉数量和冠状动脉病变的SYNTAX(紫杉醇药物涂层支架与心脏外科手术协同作用)评分用于评估冠状动脉狭窄程度。
ACS患者的ELA水平显著高于对照组(<0.01)。单支、双支和三支血管疾病患者的血浆ELA水平无显著差异。然而,在广义相加模型(GAM)中,ELA水平与Syntax I评分之间存在阈值非线性相关性(<0.001)。当ELA水平在63.47至85.49 ng/mL之间时,血浆ELA水平与Syntax I评分呈正相关。当ELA水平低于63.47 ng/mL或高于85.49 ng/mL时,血浆ELA水平与冠状动脉狭窄程度无显著关联。
本研究首次表明ACS患者血浆ELA水平升高。内源性ELA水平升高与冠状动脉狭窄严重程度相关,可能参与了ACS的发病机制。